Odapipam (; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D<sub>1</sub> receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.
It has more than 5,000-fold selectivity for the dopamine D<sub>1</sub> receptor (K<sub>i</sub> = 0.17nM) over the dopamine D<sub>2</sub> receptor (K<sub>i</sub> = 942nM). Its affinities for other dopamine receptors, such as the dopamine D<sub>5</sub> receptor, were not reported. In addition to the dopamine D<sub>1</sub> receptor, odapipam showed relatively high affinity for the serotonin 5-HT<sub>2</sub> receptor (K<sub>i</sub> = 4.5nM; 26-fold lower than for the D<sub>1</sub> receptor).
The drug was first described in the scientific literature by 1988.